Agnieszka Sapa-Wojciechowska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Agnieszka Sapa-Wojciechowska has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Adam Szeląg
Department of Pharmacology, Faculty of Medicine, Wroclaw Medical University, Mikulicza-Radeckiego 2, 50-345 Wrocław, Poland
1 shared publication - Joanna Kwiatkowska
Department of Pharmacology, Wroclaw Medical University, 50-345 Wrocław, Poland
1 shared publication - Katarzyna Haczkiewicz-Leśniak
Division of Ultrastructural Research, Faculty of Medicine, Wroclaw Medical University, 50-368 Wrocław, Poland
1 shared publication - Marzenna Podhorska-Okołów
Department of Ultrastructural Research, Wroclaw Medical University, 50-013 Wrocław, Poland
1 shared publication - Monika Skrzypiec-Spring
Department of Pharmacology, Wroclaw Medical University, 50-345 Wroclaw, Poland
1 shared publication - Tomasz Piasecki
Department of Epizootiology and Clinic of Bird and Exotic Animals, Faculty of Veterinary Medicine University of Environmental and Life Sciences Wrocław Poland
1 shared publication
Latest Publications
- Open Access
- 28 September 2021
- Published by MDPI AG in Biomolecules
- Vol. 11 (10) , 1415
HMG-CoA Reductase Inhibitor, Simvastatin Is Effective in Decreasing Degree of Myocarditis by Inhibiting Metalloproteinases Activation
Background: Acute myocarditis often progresses to heart failure because there is no effective, etiology-targeted therapy of this disease. Simvastatin has been shown to be cardioprotective by decreasing matrix metalloproteinases’ (MMPs) activity. The study was designed to determine whether simvastatin inhibits MMPs activity, decreases the severity of inflammation and contractile dysfunction of the heart in experimental autoimmune myocarditis (EAM). Methods: Simvastatin (3 or 30 mg/kg/day) was given to experimental rats with EAM by gastric gavage for 21 days. Then transthoracic echocardiography was performed, MMPs activity and troponin I level were determined and tissue samples were assessed under a light and transmission electron microscope. Results: Hearts treated with simvastatin did not show left ventricular enlargement. As a result of EAM, there was an enhanced activation of MMP-9, which was significantly reduced in the high-dose simvastatin group compared to the low-dose group. It was accompanied by prevention of myofilaments degradation and reduction of severity of inflammation. Conclusions: The cardioprotective effects of simvastatin in the acute phase of EAM are, at least in part, due to its ability to decrease MMP-9 activity and subsequent decline in myofilaments degradation and suppression of inflammation. These effects were achieved in doses equivalent to therapeutic doses in humans.
- 28 September 2021
- Published by MDPI AG in Biomolecules
- Vol. 11 (10) , 1415
Open AccessHMG-CoA Reductase Inhibitor, Simvastatin Is Effective in Decreasing Degree of Myocarditis by Inhibiting Metalloproteinases Activation
Background: Acute myocarditis often progresses to heart failure because there is no effective, etiology-targeted therapy of this disease. Simvastatin has been shown to be cardioprotective by decreasing matrix metalloproteinases’ (MMPs) activity. The study was designed to determine whether simvastatin inhibits MMPs activity, decreases the severity of inflammation and contractile dysfunction of the heart in experimental autoimmune myocarditis (EAM). Methods: Simvastatin (3 or 30 mg/kg/day) was given to experimental rats with EAM by gastric gavage for 21 days. Then transthoracic echocardiography was performed, MMPs activity and troponin I level were determined and tissue samples were assessed under a light and transmission electron microscope. Results: Hearts treated with simvastatin did not show left ventricular enlargement. As a result of EAM, there was an enhanced activation of MMP-9, which was significantly reduced in the high-dose simvastatin group compared to the low-dose group. It was accompanied by prevention of myofilaments degradation and reduction of severity of inflammation. Conclusions: The cardioprotective effects of simvastatin in the acute phase of EAM are, at least in part, due to its ability to decrease MMP-9 activity and subsequent decline in myofilaments degradation and suppression of inflammation. These effects were achieved in doses equivalent to therapeutic doses in humans.